Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World July 25, 2008 Sarah Houlton	Small is beautiful for GSK drug discovery New GlaxoSmithKline chief executive Andrew Witty is restructuring the firm's drug discovery, setting up small, highly focussed research teams that will have to bid for funding.
The Motley Fool April 5, 2011 Frank Vinluan	GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
Chemistry World May 21, 2009 Matt Wilkinson	Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.
The Motley Fool April 12, 2011 Brian Orelli	Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets.
BusinessWeek April 18, 2005 Manjeet Kripalani	India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Chemistry World June 13, 2008 Sarah Houlton	Daiichi Sankyo makes bid for Ranbaxy The combination of the two companies - one focused on research and the other predominantly on generics - bucks the trend for research-based companies selling off or spinning out their generics businesses.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
Pharmaceutical Executive April 1, 2014 Subramanian et al.	"Market-Based" Price Controls In India? Three strategic implications for pharma pricing strategies in India.
Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Pharmaceutical Executive September 1, 2010	Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development.
Pharmaceutical Executive October 1, 2011 Amrita Ghaswalla	Changing the Dialogue No industry leader is more closely associated with the goal of seeding the globe with low-cost generics than Mumbai-based Cipla Chairman Y.K. Hamied.
Pharmaceutical Executive July 3, 2007	Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work.
Pharmaceutical Executive May 1, 2012	Country Report: South Africa In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory.
Pharmaceutical Executive July 3, 2007	Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future.
Pharmaceutical Executive September 1, 2006 Jill Wechsler	Washington Report: New Partnerships Pursue Old Diseases A new wave of collaborations between industry, non-profits, and government seeks affordable treatments for neglected diseases around the world.
Pharmaceutical Executive October 1, 2011 Daniel Vasella	Heart of Success: Patient-Centric R&D Drug discovery must remain a core competency of industry. The future success of individual companies will be tightly linked to success in R&D.
Chemistry World April 1, 2015 Sanjay Kumar	Sun Pharma snares Ranbaxy in $4bn deal Sun Pharma is now the fifth largest generics drug company in the world.
BusinessWeek January 12, 2004 Manjeet Kripalani	India: Big Pharma's New Promised Land? Drugmakers are heeding the siren call of its well-trained, cheap chemists.
BusinessWeek February 27, 2006 Einhorn & Kripalani	In India, Selling Generics Used To Be So Easy Suddenly, Indian drugmakers Dr. Reddy's and Ranbaxy have a host of copycat rivals.
Pharmaceutical Executive December 1, 2008 Walter Armstrong	The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future.
Chemistry World May 3, 2012 Akshat Rathi	Ranbaxy launches new anti-malarial Synriam It is the first recently developed antimalarial that is not based on artemisinin, one of the most effective treatments for malaria, which has begun to suffer from problems with resistance in recent years.
Pharmaceutical Executive May 1, 2011 Stan Bernard	Competition 2.0: Brands vs. Generics Innovator and generics companies are colliding as they invade each other's turf.
Pharmaceutical Executive October 1, 2011	30 Years of Pharma: Perspective in Numbers, Part 3 Top 10 generics companies.
Chemistry World October 2, 2013 Phillip Broadwith	Aspen acquires anticoagulant brands South African generics manufacturer Aspen has bought two heparin-derived thrombosis drugs from GlaxoSmithKline.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Chemistry World September 3, 2014 Rajesh Parishwad	Piramal exits drug discovery in India India's Piramal Enterprises is exiting its early-stage drug discovery research and focusing on late clinical development, along with its core areas such as generics and contract research services.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool June 26, 2006 Stephen D. Simpson	Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.
Pharmaceutical Executive October 1, 2011	The Legacy of High Expectations Andrew Witty, Chairman & CEO, GlaxoSmithKline, believes the pharmaceutical industry will continue to make a significant contribution to society if it continues to improve the way it goes about its work.
The Motley Fool June 28, 2010 Luke Timmerman	Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system.
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.
Bio-IT World December 10, 2002 Jim Hall	21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
Pharmaceutical Executive April 1, 2007 Walter Armstrong	Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom.
The Motley Fool December 21, 2010 Brian Orelli	4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday.
Pharmaceutical Executive October 1, 2006 Joanna Breitstein	"I Pray for the Welfare of Your Company..." Big Pharma's drugs fill Teva Pharmaceutical's pipeline. CEO Israel Makov says he's not the enemy. To prove it, he offers lessons in survival.
Chemistry World September 10, 2015 Katrina Megget	Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions
Chemistry World April 25, 2014 Andy Extance	$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees.
Chemistry World May 16, 2013 Anthony King	GSK partners Save the Children for Africa project Pharma giant GSK is to partner the international charity Save the Children in a five year deal, which it says aims to help save the lives of one million children. The controversial compact offers a blueprint for how businesses and non-government organizations can work together, says GSK.
The Motley Fool December 1, 2011 John Grgurich	Pfizer Losing Lipitor Patent: What Investors Need to Know The patent ends today.
BusinessWeek July 14, 2003 Einhorn & Kripalani	In India a Little Lab Work and Lots of Lawyers Ranbaxy, a maker of generic drugs, must win lawsuits to grow
Chemistry World December 15, 2009 Sarah Houlton	Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu.
Bio-IT World June 2006 Michael A. Greeley	Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process.
The Motley Fool July 31, 2009 Brian Orelli	Can Emerging Markets Save Pharma? Probably not until after they emerge.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Chemistry World April 20, 2009 Phil Taylor	GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.